MASLD Research Center

Had a brilliant day as a visiting professor at PGIMER Chandigarh- thanks to @ajay_duseja for hosting me! Really enjoyed the research presentations by fellows & ward rounds followed by evening liver society forum! @drnipunverma @MASLDResearch @AASLDPresident @EASLnews @UCSDHealth

Great CME hosted by Department of Hepatology, @pgichd. Insightful discussion on recent advances in MASLD by @DrLoomba Always inspiring to see the impactful work being led by @ajay_duseja . As a trainee, grateful for the opportunity to learn from leaders in the field. @drsuniltaneja @atulsachdeva @drnipunverma @drbabupgi

A new international consensus published in @AGA_Gastro establishes a unified framework for diagnosing and staging liver disease in α-1 antitrypsin deficiency. Read more here: ow.ly/hl9350Yn4OZ @DrLoomba @MattiasMandorf1 @AleksanderKrag @PaulYKwo

Congratulations @f_tavaglione at @MASLDResearch @UCSD_GI for a fantastic paper- great to collaborate with @hanneshgstrm @EASLnews @AASLDtweets @AASLDPresident @AmerGastroAssn @AGA_Gastro health.ucsd.edu/news/press-rel…

🚀 New biomarker panel to screen for MetALD or ALD At @UCSD @DrLoomba, we developed the MetALD-ALD Prediction Index (MAPI) using sex, MCV, GGT, HDL-C, and HbA1c🧪 MAPI was externally validated at @karolinskainst 🚨 Out in @AGA_Gastro 🔗authors.elsevier.com/c/1mgKz3mEmnRPX

Factors associated with protection from MASLD in type 2 diabetes: A prospective study integrating longitudinal MRI/MRE and stable isotope tracing jhep-reports.eu/article/S2589-… @f_tavaglione nice paper! @AASLDtweets @EASLnews @MASLDResearch @UCSD_GI @UCSDHealth @AmerGastroAssn

#ColorectalCancer is increasing among younger adults, making awareness & early screening more important than ever. Rohit Loomba, MD, #UCSDHealth, joined @CBS8 to discuss why screening matters, plus the key signs and symptoms you shouldn’t ignore.@DrLoomba cbs8.com/video/news/loc…

Clinical utility of a 50% and 30% decline in MRI-PDFF in predicting fibrosis improvement in metabolic dysfunction-associated steatohepatitis - CGH cghjournal.org/article/S1542-…

Our new paper on comparative efficacy of MASH therapies in cirrhosis- FGF-21, and combination therapies may be useful in reversing MASH cirrhosis- @AASLDtweets @EASLnews @DrHuangDQ @MASLDResearch @UCSD_GI Alimentary Pharmacology & Therapeutics | onlinelibrary.wiley.com/doi/10.1111/ap…

Tonight talking about MASH including new treatments- ⁦@AjmeraVeeral⁩ in San Diego kickstarting with natural history and NITs in MASH ⁦@AASLDtweets⁩ ⁦@EASLnews⁩ ⁦@UCSDHealth⁩ ⁦@CLDFoundation⁩ - 60 registrations and a waiting list

Kickstarting the ⁦@CLDFoundation⁩ Breakthroughs in MASH Diagnosis and Management in San Diego with ⁦@MASLDResearch⁩ faculty ⁦@AjmeraVeeral⁩ and Lisa Richards, NP tonight with a full house ⁦@AASLDtweets⁩ ⁦@EASLnews⁩ ⁦@UCSD_GI⁩ ⁦

How can noninvasive tests (NITs) be used to identify and monitor response to Semaglutide in MASLD - without a liver biopsy? @DrLoomba @AASLDtweets @MonicaTincopa @LuisAntonioDiaz @MASLDResearch onlinelibrary.wiley.com/doi/10.1111/ap…

Talking about her research on NITs in MASLD in Hispanic population ⁦@MonicaTincopa⁩ ⁦@MASLDResearch⁩ ⁦@UCSD_GI⁩ presenting ⁦@SDDRC⁩ annual research symposium!! 👏 👏 👏

Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet thelancet.com/journals/lance…

New publication 📢 Monthly Efimosfermin alfa, an FGF21 analogue, shows promising results in treating liver fibrosis in MASH patients, with 45% achieving fibrosis improvement after 24 weeks of treatment. 👉authors.elsevier.com/c/1mZWaV-4XSk4l @DrLoomba @UCSD_GI

10th Annual ⁦@NashTagConf⁩ kick starting with welcome followed by year in review by ⁦@mcharltonmd⁩ - stimulating talk and full house !!!

Fatty Liver Disease, it's diagnosis and what we do next. 📺 Check out this @BritSocGastro interview by @DrLoomba , is a great snapshot of how we assess fatty liver disease, why diet matters and how we treat MASLD & MASH. @UCSD_GI @AASLDtweets @FattyLiverA

@UCSanDiego has appointed Rohit Loomba, MD, (@DrLoomba) as the inaugural John C. Martin Endowed Chair in #LiverDisease. The chair supports innovative research and treatment in liver disease, with a focus on population-based risk factors. today.ucsd.edu/story/john-c-m…

The John C. Martin Endowed Chair in Liver Disease has been awarded to @DrLoomba , recognizing his remarkable contributions to liver disease research. today.ucsd.edu/story/john-c-m…

@JosephCAhnMD @AASLDFoundation Congratulations Joseph!

An unforgettable week at #TLM25 — presented my research, received a @AASLDFoundation career development award, reconnected with old mentors and friends, and met incredible new colleagues. Grateful and inspired to keep pushing forward.